Categories: News

LaunchPad Café Ltd. Announces Closing of Transaction with Ventana Biotech, Inc. (VNTA)

LaunchPad Café Ltd. Announces Closing of Transaction with Ventana Biotech, Inc. (VNTA)

LaunchPad Café Ltd. announces that it has closed its previously announced transaction with Ventana Biotech, Inc. (OTC:VNTA) pursuant to which VNTA has purchased 100% of LaunchPad’s shares in exchange for shares in VNTA – www.launchpadcafe.net.

DENVER, June 25, 2021 (GLOBE NEWSWIRE) — LaunchPad Café Ltd. announces that it has closed its previously announced transaction with Ventana Biotech, Inc. (OTC:VNTA) pursuant to which VNTA has purchased 100% of LaunchPad’s shares in exchange for shares in VNTA.

Mr. Stephen Replin, new President and CEO of VNTA and President of LaunchPad Café said, “We are pleased to announce the closing of this important transaction for VNTA. We are now working to update the publicly available financial information for the VNTA on OTCMarkets.com The immediate goals are getting to ‘Yield Sign’ within the next two weeks and ‘Pink Current Reporting’ by mid-August. We also anticipate changing the Company’s name sometime in the coming months.”

About Ventana Biotech, Inc.:

Ventana Biotech, Inc. (OTC:VNTA) is a publicly traded Nevada company making acquisitions in the fintech and traditional specialty finance space.

About LaunchPad Café Ltd.:

LaunchPad Café, Ltd., a specialty finance Company, makes alternative funding available to entrepreneurs who are starting and growing businesses, and to those who have investment opportunities. In all cases, the two characteristics that are anticipated to be common among most borrowers from LaunchPad are that they are essentially “unbankable,” and the second is that they need to close on their funding quickly. Mr. Replin, CEO of LaunchPad Café Ltd. is the author of the book “Where to Go when The Bank Says No” –www.launchpadcafe.net.

Forward Looking Statements:

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are subject to uncertainty and may not come to fruition. Readers are cautioned not to place undue reliance on any forward-looking statement including statements that list numbers and dates.

Contact:
Stephen Replin, CEO
Stevereplin@launchpadcafe.net
303.916.3479

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2842695f-3568-44e8-b774-b2b787c8684e

Staff

Recent Posts

Vent Creativity Appoints Paul Abrams as Vice President of Sales to Lead Commercial Growth

NEW YORK--(BUSINESS WIRE)--Vent Creativity, a medical technology company advancing AI-enabled surgical planning, today announced the…

7 hours ago

AEON Clinic Announces Next Generation Medicine Congress 2026 Event: A Global Convergence on Human Longevity in Dubai

AEON Clinic Elevates Dubai to Global Hub for Longevity Science, A Definitive Four-Day Summit Defining…

7 hours ago

AI-Era Position Statement to Protect the Integrity of Healthcare, Technology, and Services Benchmarking published by Black Book Research

Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…

1 day ago

New employee representative on the Board of Directors of Novo Nordisk A/S

Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…

1 day ago

Embers to Empowerment: The Womb Room Reopens in Govans, Expanding Community-Centered Perinatal Care After Hampden Fire

Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…

1 day ago

Oxford Healthspan to Introduce New Primeadine® GF Powder Through a ‘Longevity Shot’ Experience During Grammy Week in Los Angeles

Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment Primeadine Longevity Shot Primeadine…

1 day ago